Bicara Therapeutics INC Form 4 insider transactions

Bicara Therapeutics CFO Ivan Hyep executed planned sales of common stock and option exercises on March 3 and 4, 2026, under a Rule 10b5-1 trading plan.

Bicara Therapeutics' Chief Medical Officer, David Raben, executed pre-planned sales of common stock totaling 16,500 shares in early March 2026.

RA Capital Management and its affiliated funds increased their beneficial ownership in Bicara Therapeutics Inc. through recent purchases of common stock and pre-funded warrants.

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options and subsequently sold a portion of common stock under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics Inc. President and COO Ryan Cohlhepp was granted 300,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Bicara Therapeutics CEO Claire Mazumdar received a grant of 450,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Bicara Therapeutics' Chief Medical Officer, David Raben, received a grant of 100,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Bicara Therapeutics Inc. Chief Financial Officer Ivan Hyep was granted 125,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Bicara Therapeutics' Chief Legal Officer, Lara Meisner, was granted 90,000 stock options with an exercise price of $16.76, vesting quarterly over four years.

Bicara Therapeutics' President and COO, Ryan Cohlhepp, sold 3,828 shares of common stock for approximately $18.10 per share under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics' Chief Financial Officer, Ivan Hyep, executed a pre-planned sale of 1,882 common shares after exercising stock options.

Bicara Therapeutics President and COO Ryan Cohlhepp sold 149 shares of common stock for $18.02 per share under a pre-arranged trading plan.

Bicara Therapeutics President and COO Ryan Cohlhepp exercised stock options to acquire 25,000 shares, increasing his direct ownership.

Bicara Therapeutics' Chief Medical Officer, David Raben, exercised incentive stock options to acquire 19,789 shares of common stock, increasing his direct beneficial ownership.

Bicara Therapeutics CFO Ivan Hyep executed a pre-planned sale of 9,200 common shares following the exercise of stock options.

Bicara Therapeutics CEO Claire Mazumdar exercised 29,500 stock options at $5.4537 per share, increasing her direct common stock holdings.

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options and subsequently sold a portion of his common stock holdings under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics CFO Ivan Hyep exercised stock options and subsequently sold 18,400 shares of common stock under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics President and COO Ryan Cohlhepp sold 12,500 shares of common stock after exercising options, as part of a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics Inc. CEO Claire Mazumdar exercised stock options and subsequently sold 41,163 shares of common stock under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics' Chief Medical Officer, David Raben, exercised and sold 11,000 shares of common stock in late November 2025 under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics CEO Claire Mazumdar exercised stock options and subsequently sold an equal number of common shares under a pre-arranged trading plan.

Bicara Therapeutics' President and COO, Ryan Cohlhepp, exercised stock options and subsequently sold 12,500 shares of common stock under a pre-arranged Rule 10b5-1 trading plan.

Bicara Therapeutics CEO Claire Mazumdar executed pre-planned sales of common stock following option exercises as per a Rule 10b5-1 trading plan.

Bicara Therapeutics' Chief Medical Officer, David Raben, exercised stock options and subsequently sold 22,000 shares of common stock for $18.45 per share.

Bicara Therapeutics' CFO, Ivan Hyep, exercised stock options and subsequently sold an equal number of common shares under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics CFO Ivan Hyep exercised stock options and subsequently sold shares under a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics President and COO Ryan Cohlhepp reported exercising stock options and selling common stock totaling 49,600 shares under a Rule 10b5-1 plan.

Bicara Therapeutics' Chief Legal Officer, Lara Meisner, exercised stock options and subsequently sold 33,807 shares of common stock for a profit, as per a pre-arranged 10b5-1 trading plan.

Bicara Therapeutics' Chief Legal Officer, Lara Meisner, exercised stock options and immediately sold the resulting shares on September 15, 2025, under a pre-arranged trading plan.